Windgap Medical develops patient solutions built on a patented wet/dry drug-delivery platform and autoinjector technology. Its lead program is an epinephrine autoinjector for the treatment of anaphylaxis, for which the company intends to seek FDA approval. Windgap is also advancing a novel emergency treatment for cyanide poisoning sponsored by the National Institutes of Health through a multi-year CounterACT grant led by the University of Minnesota Twin Cities. The company said it will use new funding to energize the ongoing epinephrine commercialization process and grow its pipeline of additional products that utilize the platform. Windgap’s products have not been reviewed by the FDA to date. The company is led by CEO Christopher Stepanian and CTO Brent Buchine, PhD, and is based in Watertown, MA. Windgap Medical develops a patented wet/dry drug-delivery platform. Its first product is designed for administration of epinephrine to treat anaphylaxis, and the company has additional products under development in other markets. None of Windgap’s products have been reviewed by the FDA; the company intends to seek FDA approval first for the epinephrine product. The company is led by CEO and co-founder Chris Stepanian and is based in Watertown, Massachusetts. Financially, Windgap received a strategic investment of undisclosed size. The investment was led by Shepherd Kaplan Krochuck, with participation from Molex Ventures (a subsidiary of Koch Industries). Windgap Medical is developing a smaller, more user-friendly epinephrine auto-injector with a dry, more temperature-stable formulation intended to be pocket-sized (about the size of a Bic lighter). The device is designed to make it obvious which end is the needle and to reduce user errors common with current auto-injectors. Windgap holds more than a dozen provisional patents and has patents pending covering device design and the drug formulation. The company is targeting a market release by 2018 and intends to compete in the roughly $1.3 billion auto-injector market dominated historically by the EpiPen (with >90% market share). Windgap positions its product against competitors such as Sanofi’s Auvi-Q and upcoming generic alternatives and has not disclosed pricing or reimbursement plans, leaving that to commercialization partners. The startup was a 2012 MassChallenge winner and has raised financing to support development.

Total raised

$43M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2022